SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2015 / Cilt: 6 - Sayı: 4

Prostat Biyopsisinde Siprofloksasin-Seftriakson Kombinasyon Profilaksisi; Enfektif Komplikasyonlar

Ciprofloxacin-Ceftriaxone Combination Prophylaxis for Prostate Biopsy; Infective Complications

Alim KOŞAR
Ahmet GÜZEL
Alper ÖZORAK
Sefa Alperen ÖZTÜRK
Sedat SOYUPEK
Tahsin ÇAPKIN
Murat UÇAR
Taylan OKSAY
Mustafa Burak HOŞCAN
Pages
419–422
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Ceftriaxone plus ciprofloxacin prophylaxis is safe and can be useable option for prophylaxis of prostate biopsy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To present our clinical experience about infective complications due to ultrasound guided transrectal prostate biopsy under ciprofloxacin plus thirdgeneration cephalosporin (Ceftriaxone) combination prophylaxis.
📊
Key Findings & Data:Material and Method: The 1193 patients that used combination of ceftriaxone 1 g intramuscular 1 hour before biopsy and ciprofloxacin 500 mg twice a day for 5 days after biopsy were included to study.
💡
Conclusion & Impact:Ceftriaxone plus ciprofloxacin prophylaxis is safe and can be useable option for prophylaxis of prostate biopsy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To present our clinical experience about infective complications due to ultrasound guided transrectal prostate biopsy under ciprofloxacin plus thirdgeneration cephalosporin (Ceftriaxone) combination prophylaxis. Material and Method: The 1193 patients that used combination of ceftriaxone 1 g intramuscular 1 hour before biopsy and ciprofloxacin 500 mg twice a day for 5 days after biopsy were included to study. Before biopsy, urine analysis and urinary cultures were not performed routinely. Serious infective complications such as acute prostatitis and urosepsis, causing microorganisms were evaluated. Results: Serious infective complications occurred in (1.3%) 16 patients. Fifteen of them had acute prostatitis and urine culture results were positive in 10/15 patients for Escherichia coli. The strains were uniformly resistant to ciprofloxacin. Only 1 patient had urosepsis and his blood and urine cultures demonstrated extended- spectrum β-lactamase-producing (ESBL) Escherichia coli also resistant to ciprofloxacin. Antibiotic treatment-related side effects were not observed in any patient. Discussion: Although there is not a certain procedure, ciprofloxacin is the most common used antibiotic for transrectal prostate biopsy prophylaxis. On the other hand, the incidence of ciprofloxacin resistant Escherichia coli strain is increasing. Thus, new prophylaxis strategies have to be discussed. Ceftriaxone plus ciprofloxacin prophylaxis is safe and can be useable option for prophylaxis of prostate biopsy.

Özet

Amaç: Siprofloksasin ve seftriakson (üçüncü kuşak sefalosporin) kombinasyon profilaksisi altında, ultrasonografi kılavuzluğunda transrektal prostat biyopsisi uyguladığımız hastalarda gelişen enfektif komplikasyonları sunduk. Gereç ve Yöntem: Çalışmaya biyopsiden 1 saat önce intramuskuler 1 g seftriakson ve biyopsi sonrası 5 gün, günde iki doz, oral 500 mg siprofloksasin uygulanan 1193 hasta dahil edildi. Biyopsi öncesi rutin idrar analizi ve idrar kültürü alınmadı. Akut prostatit ve ürosepsis gibi ciddi enfektif komplikasyonlar ve neden olan mikroorganizmalar değerlendirildi. Bulgular: Hastaların 16 (%1,3) sında ciddi enfektif komplikasyonlar gelişti. Onbeş hastaya akut prostatit teşhisi konuldu ve 15 hastanın 10unda idrar kültüründe Escherichia coli pozitif bulundu. Suşlar siprofloksasine dirençliydi. Sadece 1 hastada ürosepsis gelişti. Bu hastanın kan ve idrar kültüründe siprofloksasine dirençli genişletilmiş spektrumlu β-laktamaz üreten (ESBL) Escherichia coli tespit edildi. Hiçbir hastada antibiyotiklere bağlı yan etki gözlenmedi. Tartışma: Belirli bir profilaksi prosedürü olmamasına rağmen transrektal prostat biyopsi profilaksisinde siprofloksasin en yaygın kullanılan antibiyotiktir. Bununla birlikte siprofloksasin dirençli Escherichia coli suş insidansı artmaktadır. Bu nedenle yeni profilaksi stratejileri tartışılmalıdır. Seftriakson ile siprofloksasin kombinasyon profilaksisi prostat biyopsisinde güvenli ve kullanılabilir bir seçenektir. Anahtar Kelimeler İnfeksiyon; Profilaksi; Prostat Biyopsisi; Seftriakson; Siprofloksasin Abstract

🔖

Cite This Article

KOŞAR, A., GÜZEL, A., ÖZORAK, A., ÖZTÜRK, S. A., SOYUPEK, S., ÇAPKIN, T., UÇAR, M., OKSAY, T., HOŞCAN, M. B. (2022). Prostat Biyopsisinde Siprofloksasin-Seftriakson Kombinasyon Profilaksisi; Enfektif Komplikasyonlar. Journal of Clinical and Analytical Medicine, Cilt: 6 - Sayı: 4, 419–422. https://ajindex.com/articles/560956

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Schneider H, Ludwig M, Hossain HM, Diemer T, Weidner W. The 2001 Giessen Cohort Study on patients with prostatitis syndrome an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia 2003;35(5):258-62
  2. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001;17:331–41
  3. Grabe M, Bjerklund-Johansen TE, Botto H, Wullt B, Çek M, Naber KG et al. Guidelines on urological infections. European Association of Urology Arnhem, The Netherlands; 2012
  4. Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I et al. The incidences of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-5
  5. American Urological Association. Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis 2008. AUA, Washington, D.C; 2012
  6. Berger AP, Gozzi C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004;171:1478 –80
  7. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998;160:2115 –20
  8. Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011;5:CD006576
  9. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830–4
  10. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963–8
  11. Akduman B, Akduman D, Tokgöz H, Erol B, Türker T, Ayoğlu F et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011;78:250-5
  12. Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy-should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012;18(6):575-81
  13. Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R. Infection after transrectal ultrasonography-guided prost